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In this issue of Cell Stem Cell, Robin et al. (2009) demonstrate the robust hematopoietic stem cell capacity of
the human placenta. The study investigates components of the placental niche and paves the way for clinical
applications of blood production.Although there exist many embryonic
sites of hematopoietic stem cell (HSC)
emergence, the placenta has the greatest
potential for therapeutic applications
because of its size and accessibility. As
a relatively new addition to the embryonic
hematopoietic repertoire, the placenta
has only recently been demonstrated to
not only provide a niche for develop-
mental HSC expansion but also be
responsible for in situ production of
HSCs in mouse models. These qualities
are now evidenced in the human, as illus-
trated in the work of Dzierzak and
colleagues (Robin et al., 2009) published
in this issue of Cell Stem Cell.
In the mouse system, the placenta
contains fetal-derived in vitro clonogenic
hematopoietic precursors as early as
embryonic day 9 (E9), shortly after cho-
rioallontoic fusion, reaching maximal
hematopoietic potential by E12.5 (Al-
varez-Silva et al., 2003). When evaluated
for in vivo repopulating capacity, it became
clear that the placenta harbored large
numbers of HSCs, similar to the fetal liver,
and outcompeted other sites of hemato-
poiesis in repopulating activity throughout
development (Gekas et al., 2005; Otters-
bach and Dzierzak, 2005). HSCs with repo-
pulating ability were initially found in the
placenta at approximately E10.5–11.0
with a dramatic decline at E15.5, whereas
fetal liver populations remained high (Ge-
kas et al., 2005). The placental site promi-
nent for HSC residence was shown to be
the labyrinthine layer, in close approxima-
tion to the placental vasculature (Otters-
bach and Dzierzak, 2005).
Although previous studies (Gekas et al.,
2005; Ottersbach and Dzierzak, 2005)
validated the placenta as a hematopoeitic
site with repopulating capacity, the
question as to whether placental HSCsdevelop in situ was later addressed in
work conducted by Mikkola and col-
leagues (Rhodes et al., 2008). By investi-
gating a mouse model with defective
circulation (Ncx1/), Rhodes et al. were
able to demonstrate that the placenta
produced de novo HSCs with in vitro mul-
tilineage potential that appeared to arise
from the labyrinthine vasculature. The
placental HSCs expressed Runx1, a tran-
scription factor critical to definitive hema-
topoiesis, CD41 (a marker of early HSC
progenitors), and CD31 and CD34 (endo-
thelial markers also expressed by HSCs in
early development), and thus placental
HSCs exhibited profiles similar to other
embryonic HSC pools (Ottersbach and
Dzierzak, 2005; Rhodes et al., 2008).
Taken together, the mouse data strongly
argue for the addition of the placenta
to the list of embryonic hematopoietic
organs, capable of HSC emergence and
expansion, and like other sites of HSC
emergence may exhibit endothelial-
derived hematopoiesis (hemogenic endo-
thelium).
Despite the fact that both mice and hu-
mans possess hemochorial placentas, it
is unclear whether the findings of murine
placental hematopoiesis would be appli-
cable to humans. Along these lines,
a recent study by Fisher and colleagues
demonstrated that human placentas
(from 5 weeks’ gestation to term) harbor
hematopoietic cells with multilineage
in vitro clonogenic potential (Barcena
et al., 2009). The fetal cells that expressed
CD34++CD45low (and CD34+CD45low)
were noted to be greatest in number
during the embryonic phase, able to
differentiate into all lineages in vitro
(lymphoid potential of CD34+CD45low
was not studied), and maintained steady
numbers throughout gestation with local-Cell Stem Cellization to placental vasculature and
chorionic villi mesenchyme (Barcena
et al., 2009). A second study by Kuypers
and colleagues evaluated term placentas
and also noted a population of
CD34+CD45low cells; CD34+ versus
CD34++ was not distinguished (Serikov
et al., 2009). The placental CD34+CD45low
HSCs also expressed CD31, but antibody
blockade of the CXCR4 receptor (known
to mobilize HSCs) yielded primarily
CD34+CD45lowCD31 cells (Serikov et al.,
2009), suggesting that placental HSCs
egress from an endothelial association
(CD31+). Both groups also demonstrated
engraftment of human placental cells into
irradiated immunocompromised NOD/
SCID mice, either with whole placental
populations at term (Serikov et al., 2009)
orwithin the CD34++CD45low compartment
at midgestation (Barcena et al., 2009),
although the latter finding was mentioned
only as a note added to the manuscript
proof.
In this issue, Dzierzak and colleagues
provide the first formal demonstration of
human placental HSCs with clonogenic
multilineage potential in vitro, repopulat-
ing ability throughout gestation and,
even more promisingly, at term (Robin
et al., 2009). Distinct from other studies,
the authors evaluated all placental com-
partments to ensure the properties exam-
ined could be attributed to the various
placental subsets and in addition per-
formed rigorous genetic analysis to
distinguish between fetal and maternal
contributions. The authors found an
enrichment of fetal-derived CD34+ and
CD34 populations capable of in vitro
progenitor activity as early as week 6 of
gestation. Although erythroid colonies
were found in both populations through-
out gestation, the CD34+ fraction did not5, October 2, 2009 ª2009 Elsevier Inc. 351
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PreviewsFigure 1. Hematopoietic Stem Cell Emergence and Expansion in the Human Placenta
Schema represents CD34+ HSC emergence and expansion in the vascular labyrinthine layer of the
placenta. The endothelial cells are covered by perivascular pericytes that either compose or significantly
contribute to placental stromal lines known for their hemato-supportive properties.have granulocyte-macrophage or mixed
colony activity (as compared to CD34)
until 15 weeks, suggesting a maturation
process for HSCs in the placenta. Pla-
cental hematopoietic progenitors (CD34+
CD45+) were localized to placental villi
and vasculature (in agreement with pre-
vious studies). Hematopoietic engraft-
ment of NOD/SCID or RaggC/ mice by
human placental cells demonstrated
human fetal-derived multilineage engraft-
ment. Both CD34+ and CD34 fractions
exhibited repopulating capacity, although
HSC repopulation was enriched in the
CD34+ compartment of 16- to 18-week-
old placentas. Mice that received cells
dissociated from the placenta proper ex-
hibited engraftment levels similar to
human cord blood. When mice were
transplanted with cells retrieved from
collagenase-treated placental vessels
(and not enzymatic dissociation of the
placenta proper), enhanced engraftment
was observed. Although this pattern
suggests that placental HSCs reside in
close proximity to the placental vessels,
enhanced enzymatic digestion of the
placenta resulted in placental repopulat-
ing ability that approximated that of the
placental vessel fraction. Most impor-
tantly, repopulating ability was measured
at term, even after freeze-thaw cycles,
thereby paving the way for future clinical
banking of this important tissue that is
routinely discarded.
At present, both human and mouse
placentas can be categorized as true352 Cell Stem Cell 5, October 2, 2009 ª2009hematopoietic organs. Yet, the placenta
stands alone when compared to other
embryonic hematopoietic sites, in that it
allows both emergence (which historically
has been a property limited to select
embryonic arteries) and expansion (which
was thought to be the sole purview of the
fetal liver). In order to take advantage
of these properties for potential clinical
applications, insight into the regulation
of the placental niche will be required.
To this end, the authors created stromal
cell lines from placentas of various gesta-
tional ages. The placental stromal lines
displayed characteristics similar to other
hemato-supportive stroma, such as the
capacity to support robust expansion
of CD34+ cord blood cells (especially at
16–18 weeks), differentiation along var-
ious mesenchymal lineages, and pheno-
typic surface expression resembling other
published placenta lines. In addition, the
placental stromal lines expressed peri-
cyte markers shared with in situ perivas-
cular cells. Because pericytes have
recently been shown to exhibit mesen-
chymal stem cell properties (Crisan
et al., 2008), the authors suggest that peri-
cytes may play a role in the hemato-
supportive properties of the stromal lines.
Thus, the placental hematopoietic niche,
which already includes the placental
vasculature, may also incorporate peri-
vascular pericytes.
How pericytes may regulate hemato-
poiesis, and through which signaling
cascades, remains to be seen. BecauseElsevier Inc.HSCs are thought to be endothelial
derived during development, perivascular
cells may play an indirect role by acting on
the endothelium and its ability to become
hemogenic (Figure 1). Alternatively, given
that organization of a mature pericyte/
smooth muscle cell layer does not yet
occur in the intraembryonic vessels
during HSC emergence at those sites
(Wasteson et al., 2008), pericytes may
play a role in the unique ability of the
placenta to simultaneously support HSC
emergence and expansion. Interestingly,
pericytes canonically express PDFRb,
and mouse mutants of the PDGF pathway
exhibit both hematologic and placental
labyrinthine abnormalities (Ohlsson et al.,
1999). Therefore, it is possible that
PDGF signaling in pericytes may
contribute not only to placental morpho-
genesis but also to the hematopoietic
niche.
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